Serotonergic Signalling

Serotonin, or 5-hydroxytryptamine, is synthesised from dietary tryptophan by tryptophan hydroxylase, isoform 2 in brainstem raphe neurons and isoform 1 in gut enterochromaffin cells. Raphe projections reach almost the entire forebrain. Signalling terminates by reuptake through the serotonin transporter and by monoamine oxidase. The system's defining feature is receptor diversity: fourteen subtypes across seven families, all G protein-coupled except 5-HT3, which is a ligand-gated ion channel. Subtypes differ in coupling and anatomy, so a global rise in serotonin has no single coherent effect.

The pharmacology shows how much subtype selectivity matters. Selective serotonin reuptake inhibitors are approved for depression and anxiety disorders. Triptans are 5-HT1B and 5-HT1D agonists for migraine. Ondansetron is a 5-HT3 antagonist for nausea. On the other side, fenfluramine was withdrawn in 1997 after appetite-suppressant combinations were linked to valvular heart disease mediated by 5-HT2B receptors on the valves, and the ergot dopamine agonist pergolide was withdrawn in 2007 for the same reason. Fenfluramine later returned as an approved treatment for seizures in Dravet syndrome, under a programme requiring echocardiographic monitoring.

The practical rule that follows is that 5-HT2B agonism is a structural red flag for any new serotonergic agent, and that receptor-level selectivity, not simply an effect on serotonin, determines both efficacy and risk. Most of the body's serotonin sits outside the brain, so peripheral measurements carry essentially no information about central signalling.

The common overreach is a supplement or unapproved peptide described as boosting serotonin, resting on a chemical-imbalance story the field abandoned decades ago and on blood or urinary values that do not reflect brain activity.